Ascelia Pharma

Dagens aktienyheder 18/05-2026: WindowMaster, RTX, Wirtek og Ascelia Pharma

We have made only minor adjustments to our Ascelia Pharma one-pager following the Q1 2026 results. With less than two months remaining until the July 3 PDUFA date, the report itself contained limited new information, and the investment case stays largely intact.

Yesterday, we hosted an event with Magnus Corfitzen, CEO of Ascelia Pharma. The presentation focused on the financial results and regulatory milestones achieved during the first quarter, with particular emphasis on the investment case for Orviglance. The event concluded with a Q&A session, with discussion centered on the status and outlook regarding potential partners and the upcoming potential approval of Orviglance.

Ascelia Pharma is expected to release its Q1 2026 results on 12 May 2026. The following day at 11:00, CEO Magnus Corfitzen will present the results and provide an update on the company's latest developments in a live online event. The Q1 presentation arrives at a pivotal moment for Ascelia Pharma, with the FDA PDUFA decision date for Orviglance set for 3 July 2026 , and ongoing partnership discussions.

Mød ledelsen i H. Lundbeck, Wirtek, Ascelia Pharma og GrønlandsBANKEN, og stil spørgsmål til dagens investorpræsentationer

Dagens aktienyheder 12/05-2026: Pharma Equity Group, Columbus, GomSpace og Ascelia Pharma

Ascelia Pharma - et svensk-amerikansk biotekselskab med fokus på sjældne kræftsygdomme og diagnostisk billedbehandling, deltog torsdag d. 16. april på vores halvårlige seminar.

Dagens aktienyheder 24/04-2026: Agillic, Ascelia Pharma, Inderes og GrønlandsBANKEN